Ira Mellman, departing Genentech VP, cancer immunology
August 15, 2024 05:55 PM EDTUpdated August 16, 06:26 AM
People
Pharma

Genen­tech dis­solves can­cer im­munol­o­gy group, and re­search ex­ec­u­tive Ira Mell­man will leave com­pa­ny

Lei Lei Wu

News Reporter

Genen­tech is dis­man­tling its can­cer im­munol­o­gy team in a re­or­ga­ni­za­tion of its work in the field, and its VP of can­cer im­munol­o­gy, Ira Mell­man, will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times